Union européenne - français - EMA (European Medicines Agency)

alexion europe sas - sebelipase alfa - métabolisme lipidique, erreurs innées - d'autres tractus digestif et le métabolisme des produits, - kanuma est indiqué pour une thérapie de substitution enzymatique (ert) à long terme chez des patients de tout âge présentant un déficit en lipase acide lysosomale (lal)..

Union européenne - français - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hémoglobinurie paroxystique - immunosuppresseurs sélectifs - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - liés à la drogue effets secondaires et les effets indésirables - tous les autres produits thérapeutiques - pour les patients adultes traités avec un direct du facteur xa (fxa) inhibiteur (associés à l'apixaban ou rivaroxaban) lors de la reprise de l'anticoagulation est nécessaire à cause de la vie en danger ou un saignement incontrôlé.

Canada - français - Health Canada

alexion pharma gmbh - asfotase alfa - solution - 40mg - asfotase alfa 40mg - enzymes

Canada - français - Health Canada

alexion pharma gmbh - asfotase alfa - solution - 40mg - asfotase alfa 40mg - enzymes

Canada - français - Health Canada

alexion pharma gmbh - asfotase alfa - solution - 40mg - asfotase alfa 40mg - enzymes

Canada - français - Health Canada

alexion pharma gmbh - asfotase alfa - solution - 40mg - asfotase alfa 40mg - enzymes

Canada - français - Health Canada

alexion pharma gmbh - asfotase alfa - solution - 100mg - asfotase alfa 100mg - enzymes

Canada - français - Health Canada

alexion pharma gmbh - Éculizumab - solution - 10mg - Éculizumab 10mg - complement inhibitors

Union européenne - français - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - agents antinéoplasiques - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.